![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Celoxica | LSE:CXA | London | Ordinary Share | GB00B0L9TZ33 | ORD 1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 0.20 | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
RNS Number:3919F Celoxica Holdings PLC 09 October 2007 9 October 2007 CELOXICA HOLDINGS PLC ("CELOXICA" OR "THE COMPANY") Placing of New Ordinary Shares to raise approximately #0.66 million Celoxica Holdings plc (AIM: CXA) - a provider of electronic system level (ESL) design technology for the embedded systems and accelerated computing markets, today announces that 14,000,000 new ordinary shares of 1p each in the capital of the Company (the "Placing Shares") have been placed by Arbuthnot Securities Limited with institutional, trade and other investors at a price of 4.75p per share to raise approximately #0.66 million before expenses (the "Placing"). The Placing Shares will represent approximately 16.6 per cent. of the Company's enlarged issued share capital. The net proceeds of the Placing will be used for working capital purposes. Application has been made to the London Stock Exchange for the Placing Shares to be admitted to trading on AIM. The Placing Shares will rank pari passu with the existing issued ordinary shares of 1p each in the capital of the Company ('Ordinary Shares'). The Placing is conditional, inter alia, on the admission of the Placing Shares to AIM becoming effective ('Admission'), which is expected to occur on 10 October 2007, when dealings in the Placing Shares are expected to commence. Following Admission, the Company's enlarged issued share capital will comprise 84,307,434 ordinary shares with voting rights. The Company does not hold any shares in treasury. This figure of 84,307,434 ordinary shares may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change in their interest in, the share capital of the Company under the FSA's Disclosure and Transparency Rules. Jack Fryer, Chairman commented, "Since the appointment of our new CEO, Lee Staines, we have seen significant levels of interest in our high performance computing solutions, in particular in the international banking and life sciences sectors where increased computing speed can yield significant competitive advantage. They are genuine indicators of the much broader appeal and adoption of our solution in these and other industries. We believe that the potential demand for our technology and current market interest warrants continued focused investment. The additional funds will enable the Company to strengthen its balance sheet and enable it to take advantage of the opportunities that exist in the Accelerated Computing market where our solutions are now gaining market acceptance. We would like to thank our existing and new shareholders for their support." ENQUIRIES Celoxica Holdings plc Tel. +44 (0)1235 863 656 Lee Staines, CEO Michelle Young, CFO ICIS Tel. +44 (0) 20 7651 8688 Tom Moriarty Caroline Evans-Jones Arbuthnot Tel. +44 (0) 20 7012 2000 Tom Griffiths Alasdair Younie END This information is provided by RNS The company news service from the London Stock Exchange END IOEILFVLITLAIID
1 Year Celoxica Chart |
1 Month Celoxica Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions